It was also reported that KDM2B, as a bona fide oncogene, directly binds to and activates OXPHOS genes, not glycolytic-related genes, and subsequently contributes to the development of leukemia involving metabolic proliferative advantage [11]. This evidence concerns the gene KDM2B and leukemia.